$27.51▼-0.30 (-1.08%)
Extended:$27.51+0.00 (+0.00%)· 8:40 PM ET
Immunocore Holdings plc (IMCR)
R&D to Revenue
68.71%
Fiscal year · Period ending:

IMCR R&D to Revenue
Latest reported68.71%period ending
Latest reported68.71%period ending
IMCR FY R&D/Revenue (319.72% → 68.71%)
Latest values, visible window
High-resolution chart · PNG
What is r&d to revenue?
R&D spending as percentage of revenue.
IMCR r&d to revenue history
Annual fiscal periods. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D to Revenue |
|---|---|
| 68.7145% | |
| 71.5534% | |
| 65.568% | |
| 58.454% | |
| 274.7725% | |
| 248.4193% | |
| 389.5399% | |
| 353.3229% | |
| 423.3446% | |
| 279.5082% | |
| 193.1143% | |
| 191.3337% | |
| 319.717% |
Explore More
IMCR Financial Metrics
Explore 130+ historical metrics & ratios
Stock Comparison
Compare equities side by side
52-Week Highs Breakout
Stocks breaking to new annual highs
52-Week Lows Oversold
S&P 500 oversold value screener
Trending Momentum
Relative strength momentum leaders
Earnings Calendar
Upcoming earnings dates & reports
S&P 500 Screener
Filter and sort all 500 stocks
Market Movers
Today's biggest gainers and losers
Market Heatmap
Visual sector performance